PubMed Health⌕ Search

Biomedical subjects

S Ohsugi

Publications and source records attributed to S Ohsugi.

24 records · Page 2Linked to original sources

[Clinical application of body surface mapping and its limitations].

The importance of detecting the high fidelity electrical activity of the heart was cited in respect to making diagnosis and providing optimal treatment. Standard 12 lead electrocardiograms (ECG) and vectorcardiograms (VCG) are used in daily practice with well-documented theoretical and experimental bases. However, this system is somewhat inadequate because of its simplicity both in records and basic assumptions. The development of a better lead system is thus mandatory for a high diagnostic sensitivity and specificity and for both qualitative and quantitative assessments of collected data. In recent years, great progress has been promised in "body surface mapping methods" by the medical application of computer technology, providing abundant information including four-dimensional displays; two-dimensional surface spreads of electricity as well as the magnitudes and time references. This method appears to be a powerful diagnostic tool, despite problems inherent in ECG and some unfavorable aspects yet to be settled. The present status, prospects and limitations of this new, powerful strategy are discussed.

Aged↗

[Experimental and clinical studies on latamoxef in the perinatal period].

Pharmacokinetics and clinical studies on the perinatal use of latamoxef (LMOX, Shiomarin), a new parenteral oxacephem antibiotic, were carried out and the results obtained were as follows: After LMOX was intravenously given to mother at a dose of 1 g, the umbilical cord serum concentration of LMOX reached to peak with 18.4 micrograms/ml in 1 hour 20 minutes and its concentration was higher than the maternal serum after 2 hours 25 minutes and decreased gradually (T 1/2 beta = 1.61 hours). The materno-fetal transfer of LMOX was 71.0%. LMOX showed the good transfer as well as other cephalosporins. After LMOX was intravenously administered to mother at a dose of 1 g, LMOX concentration in milk wasn't detectable up to 12 hours. LMOX was intravenously administered to 18 cases with premature rupture of membrane, at a daily dose of 2 g for 3--6 days. The prophylactic effects were observed in all cases, both mother and neonate. No adverse effects were observed in mother except for 1 case with low grade abnormality of S-GPT, transiently. We observed 3 neonates with jaundice (total bilirubin greater than or equal to 17.0 mg/dl) probably not related to LMOX. It is concluded that LMOX is less toxic, safe and clinically useful antibiotic for the treatment of perinatal infections.

Bacterial Infections↗